Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
32.42
-0.14 (-0.43%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.

It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma.

Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial.

Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings plc
Immunocore Holdings logo
Country United Kingdom
Founded 2008
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 497
CEO Bahija Jallal

Contact Details

Address:
92 Park Drive, Milton Park
Abingdon, OX14 4RY
United Kingdom
Phone 44 12 3543 8600
Website immunocore.com

Stock Details

Ticker Symbol IMCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $26.00
CIK Code 0001671927
CUSIP Number 45258D105
ISIN Number US45258D1054
SIC Code 2836

Key Executives

Name Position
Dr. Bahija Jallal Ph.D. Chief Executive Officer and Executive Director
Brian R. Di Donato M.B.A. Executive Vice President, Chief Financial Officer and Strategy
Tina St. Leger Chief Human Resources Officer
Dr. David Berman M.D., Ph.D. Executive Vice President of Research and Development
John Trainer M.B.A. SVice President and Chief Operating Officer
John Goll III SVice President, Finance and Chief Accounting Officer
Annelise Vuidepot Ph.D. Senior Vice President, Chief Technology Officer and Research and UK Site Lead
Sean D. Buckley Vice President and Chief Information Officer
Clayton Robertson Head of Investor Relations
Lily Margaret Hepworth Senior Vice President, General Counsel and Company Secretary

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 8-K Current Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 8-K Current Report
Nov 6, 2024 10-Q Quarterly Report
Sep 16, 2024 8-K Current Report
Sep 10, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals